Back to Search Start Over

Characterizing <scp> SOD1 </scp> mutations in Spain: The impact of genotype, age and sex in the natural history of the disease

Authors :
Juan F, Vázquez-Costa
Daniel, Borrego-Hernández
Carmen, Paradas
María Teresa, Gómez-Caravaca
Ricardo, Rojas-Garcia
Luis, Varona
Mónica, Povedano
Tania, García-Sobrino
Ivonne, Jericó Pascual
Antonio, Gutiérrez
Javier, Riancho
Janina, Turon-Sans
Abdelilah, Assialioui
Jordi, Pérez-Tur
Teresa, Sevilla
Jesús, Esteban Pérez
Alberto, García-Redondo
Source :
European Journal of Neurology. 30:861-871
Publication Year :
2023
Publisher :
Wiley, 2023.

Abstract

The aim of this study is to describe the frequency and distribution of SOD1 mutations in Spain, and to explore those factors contributing to their phenotype and prognosis.Seventeen centres shared data on amyotrophic lateral sclerosis (ALS) patients carrying pathogenic or likely pathogenic SOD1 variants. Multivariable models were used to explore prognostic modifiers.In 144 patients (from 88 families), 29 mutations (26 missense, 2 deletion/insertion and 1 frameshift) were found in all 5 exons of SOD1, including 7 novel mutations. 2.6% of ALS patients (including 17.7% familial and 1.3% sporadic) were estimated to carry SOD1 mutations. Its frequency varied considerably between regions, due to founder events. The most frequent mutation was p.Gly38Arg (n = 58), followed by p.Glu22Gly (n = 11), p.Asn140His (n = 10), and the novel p.Leu120Val (n = 10). Most mutations were characterized by a protracted course, and some of them by atypical phenotypes. Older age of onset was independently associated with faster disease progression (exp(Estimate) = 1.03 [0.01, 0.05], p = 0.001) and poorer survival (HR = 1.05 [1.01, 1.08], p = 0.007), regardless of the underlying mutation. Female sex was independently associated to faster disease progression (exp(Estimate) = 2.1 [1.23, 3.65], p = 0.012) in patients carrying the p.Gly38Arg mutation, resulting in shorter survival compared with male carriers (236 vs 301 months).These data may help to evaluate the efficacy of SOD1 targeted treatments, and to expand the number of patients that might benefit from these treatments.

Subjects

Subjects :
Neurology
Neurology (clinical)

Details

ISSN :
14681331 and 13515101
Volume :
30
Database :
OpenAIRE
Journal :
European Journal of Neurology
Accession number :
edsair.doi.dedup.....0ce4963f01646dbbc403401b141a2765
Full Text :
https://doi.org/10.1111/ene.15661